Satlin A, Wang J, Logovinsky V, Berry S, Swanson C, Dhadda S, Berry DA. Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease. Alzheimers Dement (N Y). 2016 Jan;2(1):1-12. Epub 2016 Feb 4 PubMed.

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

Therapeutics

  1. Leqembi

News

  1. Drug Trials in Frontotemporal Dementia: Can Field Push Forward Together?
  2. Coming to a Center Near You: GAP and EPAD to Revamp Alzheimer’s Trials
  3. Topline Results: 18 Months of BAN2401 Might Work
  4. BAN2401 Removes Brain Amyloid, Possibly Slows Cognitive Decline